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Achieving the millennium development goals for health
Cost effectiveness analysis of strategies to combat malaria in
developing countries
Chantal M Morel, Jeremy A Lauer, David B Evans
This article is part of a series examining the cost effectiveness of strategies to achieve the millennium development goals for health
Abstract
Objective To determine the cost effectiveness of selected
malaria control interventions in the context of reaching the
millennium development goals for malaria.
Design Generalised cost effectiveness analysis.
Data sources Efficacy data came from the literature and
authors’ calculations supported by expert opinion. Quantities
for resource inputs came from the literature and from expert
opinion; prices came from the WHO-CHOICE database.
Methods Costs were assessed in year 2000 international dollars,
and effects were assessed as disability adjusted life years averted
by a 10 year implementation programme. Analysis was
restricted to sub-Saharan regions where the most deadly form
of malaria, Plasmodium falciparum, is most prevalent. The impact
on population health for various interventions, and their
combinations, was evaluated at selected coverage levels by using
a state-transition model. Sensitivity analysis was done for age
weights and discounting.
Results High coverage with artemisinin based combination
treatments was found to be the most cost effective strategy for
control of malaria in most countries in sub-Saharan Africa.
Conclusions A much larger infusion of resources than those
currently available is needed to make headway in the fight to
roll back malaria. On cost effectiveness grounds, in most areas
in sub-Saharan Africa greater coverage with highly effective
combination treatments should be the cornerstone of malaria
control. However, treatment alone can achieve less than half the
total benefit obtainable through a combination of
interventions—scaling up the use of impregnated mosquito nets
or indoor spraying with insecticides is also critical. Intermittent
presumptive treatment of pregnant women can bring a small
but important additional health gain at relatively low cost.
Introduction
Each year, more than one million people, mostly children and
pregnant women, die from malaria. The human toll is tragic, and
the economic cost is enormous.1 2 Most of these deaths could be
avoided, however, as effective and affordable ways to prevent and
treat malaria exist. In recognition of the scope of the problem,
malaria control is embedded in one of the millennium develop-
ment goals of the United Nations: to “combat HIV/AIDS,
malaria and other diseases.”3
Although insufficient data are available to fully assess global
experience since 2000, malaria related mortality seems to have
increased since 1990, probably owing to a combination of
factors, including increasing exposure to the disease,4 increasing
resistance to antimalarial drugs,5 and stagnant levels of coverage
with interventions (R W Snow, personal communication, 2005).
Complex emergencies and resistance to insecticides have also
contributed.6 Achieving the millennium development goals
clearly requires a massive scaling up of interventions against
malaria.
However, it is important to ask whether current interventions
are used appropriately and what is the most cost effective way to
scale up activities to the levels needed. In particular, which
prevention or treatment strategies, and what combination, are
most effective and where? We use a generalised cost effectiveness
analysis to examine the costs and effects of scaling up seven
interventions against malaria and their most promising
combinations. This paper deviates from others in this series7 by
focusing only on sub-Saharan Africa, where 90% of deaths from
malaria occur.8
Whereas most economic studies have compared the relative
cost effectiveness of implementing interventions for prevention
or treatment individually—that is, considering the best use of
small amounts of additional resources—this study used a gener-
alised framework allowing for interactions, as well as for consid-
eration of whether current practice is optimal and what the
implications are of massively scaling up.
Methods
Geographical focus
We focused on two sub-Saharan African regions: Afr-E
(predominantly Southern and Eastern Africa), defined as
African countries with high child mortality (all causes) and very
high adult mortality (all causes), and Afr-D (predominantly
Western Africa), African countries with high child mortality and
high adult mortality. Table A on bmj.com gives a list of the coun-
tries by region.
Both regions are predominantly areas with endemic high
transmission of malaria due to Plasmodium falciparum, although
the burden of disease differs somewhat. According to the World
Health Report 2000, incidence of symptomatic malaria in
children aged under 5 years was 1436 per thousand in Afr-D,
whereas in Afr-E it was 1184 per thousand; these differences are
Extra tables and figures and an appendix are on bmj.com
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due to patterns of urbanisation and the elevation of populated
sites. In Afr-E, cause specific child mortality is slightly higher at 8
per thousand as opposed to 7 per thousand in Afr-D.
Interventions
A limited number of means are available to fight malaria.
Preventive interventions, based on vector control, include insec-
ticide treated bed nets and indoor residual spraying. For
treatment of malaria, several drugs exist and a few are relatively
inexpensive. However, resistance to most drugs is growing
rapidly. Recently, combination treatments with and without
artemisinin derivatives have been tested and found not only to
be effective but also to slow the growth of resistance.9
Intermittent treatment of pregnant women—aimed largely at
reducing neonatal mortality—is also an option. We evaluated
seven individual interventions and combinations thereof (box 1).
Some countries in sub-Saharan Africa still officially
recommend chloroquine as first line treatment for malaria
despite increasing resistance and declining cure rates. Although
others have moved to sulfadoxine-pyrimethamine, resistance has
also compromised its effectiveness. As a result, awareness is
growing of the need to increase the use of artemisinin derivatives
(especially in combination treatment), as resistance to these
compounds is still extremely low (even non-existent) in
sub-Saharan Africa.10 In this study, we evaluated the cost
effectiveness of chloroquine, sulfadoxine-pyrimethamine, non-
artemisinin based combinations, and artemisinin based combi-
nations as first line treatment (we did not consider complicated
malaria needing admission to hospital).
Population at risk and coverage
We evaluated interventions at 50%, 80%, and 95% target
coverage to allow for unit costs and effectiveness that may vary
with coverage.We estimated effective coverage as target coverage
multiplied by population at risk.8 We based region-wide
estimates of population at risk (the proportion living in a malaria
endemic area: 98% for Afr-D and 69% for Afr-E) on country
specific figures published in 2003.8 Table 1 shows estimates of
current coverage,8 used for calculating the null scenario.7
Estimating the net effectiveness of interventions
We expressed the efficacy of bed nets and indoor spraying as a
reduction in incidence and, thereby, a reduction in mortality,
modelled here through case fatality (table 2). We estimated the
net effectiveness of treatment, taking into account patients’
behaviour (adherence to the regimen), pharmacokinetics (prob-
ability of success when the regimen is not followed), and
biogenetics (resistance of the parasite to the drug). These factors
(table 3) determine the number of expected treatment failures,11
which we subtracted from a common baseline of 98% efficacy.
We reduced the net effectiveness of bed nets, but not spraying, to
account for imperfect adherence. Table 4 shows estimates of net
effectiveness. Table B on bmj.com reports the detailed
assumptions on effectiveness.
A population model12 combined estimates of incidence,
prevalence, and mortality (table 5)13 with estimates of prevalence
and severity from the burden of disease study to project the
population impact of intervention scenarios in terms of healthy
Box 1: Interventions evaluated
• Insecticide treated bed nets (ITN)
• Indoor residual spraying (IRS)
• Case management with chloroquine (CQ)
• Case management with sulfadoxine-pyrimethamine (SP)
• Case management with non-artemisinin based (CQ-SP)
combination treatment (Comb)
• Case management with artemisinin based combination
treatment (ACT)
• Intermittent presumptive treatment with SP in pregnancy
(IPTp)
(See appendix on bmj.com for details)
Table 1 Current coverage* with selected malaria control interventions
Intervention Afr-D (%) Afr-E (%)
Case management with chloroquine 23 27
Case management with sulfadoxine-pyrimethamine (SP) 3 3
Case management with non-artemisinin based combination
treatment
0 0
Case management with artemisinin based combination
treatment
0 0
Insecticide treated bed nets 2 2
Indoor residual spraying 0 3
Intermittent presumptive treatment with SP in pregnancy 0 0
*Percentage of people at risk who are given the drug at outpatient clinic or antenatal clinic,
sleep under an insecticide treated net, or live in a house that has been sprayed.
Table 2 Baseline efficacy (both Afr-D and Afr-E)
Intervention
Baseline
reduction in
incidence (%)
Baseline
reduction in case
fatality* (%)
Insecticide treated bed nets 50 20
Indoor residual spraying 50 20
Case management with chloroquine 0 98
Case management with sulfadoxine-pyrimethamine
(SP)
0 98
Case management with non-artemisinin based
combination treatment
0 98
Case management with artemisinin based combination
treatment
0 98
Intermittent presumptive treatment with SP in
pregnancy
0 5
*Before patients’ adherence and parasites’ drug resistance are taken into account.
Table 3 Parameters used for the calculation of net effectiveness
Intervention
Resistance Behavioural/drug characteristics
R0 r Adherence (%)
Probability of success when not
fully compliant (%)
Insecticide treated bed nets – – 65 0
Indoor residual spraying – – 100 0
Case management with chloroquine 0.3 0.1 40 20
Case management with sulfadoxine-pyrimethamine (SP) 0.1 0.4 90 0
Case management with non-artemisinin based combination treatment 0.1 0.1 35* 45
Case management with artemisinin based combination treatment 0.001 0.05 40† 45
Intermittent presumptive treatment with SP in pregnancy 0.1 0.1 80 10
*Chloroquine-SP assumed to be coadministered.
†Combination assumed to be blister packed, co-formulated, or both.
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years of life lived.7 Differences in total population healthy years
under the intervention and baseline scenarios are expressed as
disability adjusted life years (DALYs) averted.
Costs
Estimated costs measure the value of resources needed to
provide the intervention7 and are expressed in international dol-
lars ($int, a hypothetical unit of currency that has the same pur-
chasing power that the US$ has in the United States at a given
point in time, thus showing the average value of local currency
units within each region’s borders). We calculated costs in the
light of experience from effectiveness trials, using data from the
WHO-CHOICE database, existing literature, and expert
opinion.7 As we explicitly assumed training of human resources
to be a substantial part of malaria interventions, training costs
are reported separately. We used the CostIt model (WHO, 2002)
to aggregate cost components and total costs for the 10 year
implementation horizon. Details of the approach are discussed
by Baltussen et al.14
Unit costs—We obtained unit costs of inputs, such as
salaries, capital equipment, drugs, storage, buildings, office
supplies, and furniture from a review of the literature
supplemented by primary data from several countries (a full list
of estimated unit costs is available at www.who.int/evidence/cea).
Additional details can be found in Johns et al, Johns and Baltus-
sen, and Adam et al.15–17
Distribution costs—We assumed distribution costs to be most
sensitive to changes in coverage levels and calculated them with
a standard mark-up based on the average of free on board; cost,
insurance, and freight; and additional trade related distributional
costs.15 16
Media costs—A substantial component of malaria control is
creating public awareness of and demand for health services. We
accordingly included media costs for all interventions and
estimated them according to whether they consisted of a
centrally determined policy change (for example, case manage-
ment guidelines) or were intended to change population behav-
iour (for example, insecticide treated bed nets).We included both
public campaigns (all interventions) and targeted social market-
ing (bed nets only, through an extensive level of outreach). We
obtained benchmarks from cost analyses of existing malaria
control programmes in sub-Saharan Africa.18
Labour costs—We estimated labour costs according to the
educational level of the worker—for example, administrative staff
or medical staff—and the number of full time equivalents needed
for administration, training, or delivery of the intervention.
Cost profiles— Figures 1 and 2 summarise cost profiles for
95% coverage (generally the most efficient coverage level) by
patient, programme, and training costs. Note that for some inter-
ventions patient costs are the smallest proportion of total costs.
Results
Population level cost effectiveness estimates for individual and
combined interventions are shown in table 6 (dominant
interventions only) and in figures 3 and 4 (all interventions; fig-
ures A and B on bmj.com give more detail). Complete results are
reported in table C on bmj.com.
The “expansion paths” in figures 3 and 4, described in the
methods paper for this series,7 show the order in which interven-
Table 4 Net effectiveness of the interventions
Intervention
Reduction in
incidence (%)
Reduction in case
fatality (%)
Insecticide treated bed nets 50 20
Indoor residual spraying 50 20
Case management with chloroquine – 27
Case management with sulfadoxine-pyrimethamine
(SP)
– 44
Case management with non-artemisinin based
combination treatment
– 48
Case management with artemisinin based
combination treatment
– 63
Intermittent presumptive treatment with SP in
pregnancy
– 3.4
Table 5 World Health Organization estimates of the burden of malaria
Incidence Deaths DALYs
Afr-D 176 547 940 515 528 19 088 877
Afr-E 163 442 874 470 845 17 680 061
Worldwide 381 987 866 1 120 697 41 998 576
DALY=disability adjusted life year.
Source: WHO programme on global burden of disease.
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Fig 1 Cost profile of interventions at 95% coverage, Afr-D. See box 1 for abbreviations
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tions would be selected at different levels of resource availability.
Notable differences exist between the regions. In Afr-D, case
management with artemisinin based combination treatments at
80% target coverage is the most cost effective intervention over-
all and would be the first choice where resources are limited,
whereas a target coverage of 95% is needed in Afr-E. In Afr-D,
the second intervention on the path represents an increase in
coverage with artemisinin based combination treatment. In both
regions, however, use of insecticide treated bed nets (95% cover-
age) would be added after coverage with artemisinin based com-
bination treatment reaches 95%, although in Afr-D intermittent
presumptive treatment with sulfadoxine-pyrimethamine in
pregnancy (95% coverage) would be added at the same stage. In
both regions, the ultimate stage involves the use of case manage-
ment with artemisinin based combination treatment, insecticide
treated nets as well as indoor residual spraying, and intermittent
presumptive treatment in pregnancy, all at 95% coverage.
All malaria interventions are highly cost effective, with aver-
age cost effectiveness ratios (except intermittent presumptive
treatment with sulfadoxine-pyrimethamine in pregnancy) in the
order of 10-100 $int/DALY averted. Nevertheless, the size of
potential health gains, as well as incremental cost effectiveness
ratios, are more favourable in Afr-D than in Afr-E, as a higher
proportion of the population is at risk in Afr-D. That allows more
people to be covered, thereby reducing the costs per person cov-
ered (fig 5, fig 6, table 6).
Discussion
Principal findings
Progress towards the millennium development goals has been
disappointing and major action is needed if sub-Saharan Africa
is to achieve the malaria specific target. Although external assist-
ance is critical, countries also need to re-evaluate current strate-
gies (box 2). A distinguishing characteristic of this analysis is the
health system focus, integrating evidence about costs and
effectiveness at a level relevant for policy makers.
Recent developments such as the Global Fund to Fight
AIDS, Tuberculosis and Malaria, and the interest of various
foundations, promise increased funding for malaria control. To
date, however, attention has been focused on the drugs, other
expendables, and, to a limited degree, additional staffing needed
to scale up health interventions. This narrow focus ignores the
additional system resources needed to implement and sustain a
massive scale up of activity, as well as the relatively fixed
constraints on existing staff time and health facilities. Our results
suggest that the costs of reaching agreed targets are considerably
greater than the costs that receive most current attention.
Artemisinin based combination treatments are more expen-
sive than other drugs, and, in the short term, non-artemisinin
based combinations such as amodiaquine-sulfadoxine-
pyrimethamine might be used as an interimmeasure.19 However,
as resistance to these drugs is increasing, recommendations
should be guided by local resistance patterns,20 and a full switch
to artemisinin based combinations should be seriously
considered in all areas with high transmission of drug resistant P
falciparum malaria.
Differences from other studies
This analysis differs from previous studies for malaria in that we
have specifically assessed combinations of interventions, rather
than assuming that costs and effects sum up when interventions
are used concurrently. Such studies can be misleading at worst,
and, at best, decision makers lack necessary information about
relevant combinations.
In the only previous study analysing sub-Saharan Africa,
Goodman et al found the cost/DALY averted of insecticide
treated bed nets to be $19-85 (US$, 1995) compared with $16-29
for indoor residual spraying.21 The estimates presented here
(z30 $int /DALY for either intervention at 95% coverage in
Afr-D and z40 $int/DALY at 95% coverage in Afr-E) are
roughly comparable. However, what does not emerge from typi-
cal cost effectiveness trials is the conclusion that implementing
spraying and nets together has a cost effectiveness ratio roughly
similar to that of either one alone (z35 $int/DALY at 95% cov-
erage in Afr-D and z48 $int/DALY at 95% coverage in Afr-E),
from the realisation of substantial efficiencies due to shared costs
(reducing the unit costs of both) counterbalanced by the reduced
health benefits resulting from adding spraying to widespread use
of bed nets.
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Fig 2 Cost profile of interventions at 95% coverage, Afr-E. See box 1 for abbreviations
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Limitations of the analysis
The relative effectiveness of spraying and nets has been
debated.22 23 Although we have assumed that they are equally
effective in reducing morbidity and mortality, their respective
advantages in a given setting will depend on whether mosquitoes
are endophilic, the length of time they rest indoors,24 and the
time children go to bed.
People’s willingness to use bed nets effectively is often
reduced by user charges and the need to reimpregnate nets if
they are not long lasting. Moreover, nets must be kept in good
condition and used consistently despite their at times
uncomfortable insulating properties.25
Indoor residual spraying, on the other hand, is generally paid
for and carried out by public authorities once or twice a year,
which in theory makes adherence less burdensome; however,
house owners may replaster or paint over recently sprayed walls
because of the smell of insecticide or visible deposits,23 and resi-
dents must be willing to let sprayers into their homes.
Furthermore, the relative effectiveness of these interventions will
depend on local transmission patterns. For example, in
epidemic-prone areas, spraying is likely to be an effective emer-
gency measure as it can be implemented relatively quickly and
needs less logistic effort than a bed net campaign.25
Our assumptions about the effectiveness of intermittent pre-
sumptive treatment with sulfadoxine-pyrimethamine in preg-
nancy were very conservative. We did not include health benefits
for the mother, and the effect on the infant was limited to a
reduction in case fatality due to malaria in the first year of life.
Table 6 Costs, effectiveness, and cost effectiveness of the health
maximising set of interventions (see table C on bmj.com for detailed results
for all interventions)
Region and intervention
Average
yearly
costs ($int)
Average yearly
effectiveness
(DALYs
averted)
Average
cost
effectiveness
($int/DALY
averted)
Incremental
cost
effectiveness
($int/DALY
averted)
Afr-D
Case management with
artemisinin based
combination therapy (80%
coverage)
72 386 626 7 771 018 9 9
Case management with
artemisinin based
combination therapy (95%
coverage)
95 609 717 9 254 473 10 10
Insecticide treated bed nets
plus case management with
artemisinin based
combination therapy plus
intermittent presumptive
treatment in pregnancy
(95% coverage)
315 546
119
12 972 791 24 59
Indoor residual spraying plus
insecticide treated bed nets
plus case management with
artemisinin based
combination therapy plus
intermittent presumptive
treatment in pregnancy
(95% coverage)
467 673
321
14 561 792 32 96
Afr-E
Case management with
artemisinin based
combination therapy (95%
coverage)
73 000 256 5 886 159 12 12
Insecticide treated bed nets
plus case management with
artemisinin based
combination therapy (95%
coverage)
254 755
715
9 138 452 28 56
Indoor residual spraying plus
insecticide treated bed nets
plus case management with
artemisinin based
combination therapy (95%
coverage)
441 216
954
10 721 678 41 118
Indoor residual spraying plus
insecticide treated bed nets
plus case management with
artemisinin based
combination therapy plus
intermittent presumptive
treatment in pregnancy
(95% coverage)
442 342
075
10 729 154 41 151
DALY=disability adjusted life year; $int=international dollar.
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Costing of intermittent presumptive treatment was as part of a
routine antenatal package of care with only the incremental costs
of dedicated activities considered.
Owing to lack of data on reductions in all cause mortality, we
assumed that when drugs are taken under ideal conditions they
are 98% effective in preventing cause specific mortality.
Although we did try to account for parasite resistance, imperfect
adherence to treatment, and pharmacokinetic properties, actual
effectiveness is likely to include factors omitted in the analysis.
Modelling implementation over a 10 year period, moreover, may
not fully capture the contrast between drugs with high versus low
growth rates of resistance (for example, sulfadoxine-
pyrimethamine v artemisinin based combination treatment).
Consequently, our estimate of the cost effectiveness of artemisi-
nin based combination treatments may be conservative
compared with when a longer term perspective is taken.26 Finally,
the study allows no conclusions to be drawn about financing
methods, which can be of utmost importance.27
Implications of the study
In conclusion, with the availability of increased international
funding, a re-evaluation of existing and potential strategies is
appropriate. An adequate portion of new funds should be
allocated to strengthening the health system components of
malaria interventions, which will determine the long term viabil-
ity of these activities.
On purely cost effectiveness grounds, this study suggests that
most countries in sub-Saharan Africa should be moving to com-
bination therapy with new drugs as rapidly as possible and that
efforts should be regenerated to ensure that interventions based
on prevention, such as nets and spraying, are scaled up
appropriately. Even where the health system is weak, prevention
will never be a stand alone strategy, as informal distribution
mechanisms ensure the availability of antimalarials—both
effective and highly ineffective—even in the most isolated areas.
All attempts should be made to ensure that the antimalarials that
are accessed are indeed those that work. These are relatively sim-
ple messages, but ones that remain robust even when underlying
assumptions are varied significantly.
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Box 2: Main messages—malaria and the millennium
development goals
• Five years on from the declaration of the millennium
development goals, progress in controlling malaria remains
uncertain, particularly in sub-Saharan Africa
• Health system decision makers in most countries in
sub-Saharan Africa (see text for details) should consider
switching treatment strategies to artemisinin based combinations
as the foundation of effective malaria control
• Reinvigorating efforts to scale up use of impregnated mosquito
nets and indoor spraying with insecticides is critical
• Where these interventions are being successfully implemented,
intermittent presumptive treatment of pregnant women can
bring a small but important additional health gain
• A much larger infusion of resources than those currently
available is needed to make headway in the fight to roll back
malaria
What is already known on this topic
Insufficient data are available to fully assess global malaria
trends since 2000, but malaria related mortality seems to
have increased since 1990
Despite the existence of effective preventive and curative
strategies, current malaria control in sub-Saharan Africa
remains poor
Achieving the malaria specific millennium development
goal requires a massive scaling up of interventions in
sub-Saharan Africa
What this study adds
This study quantifies the advantages of shifting resources
towards artemisinin based combination treatment, as well as
of using preventive and curative interventions in
combination
A much larger infusion of resources than those currently
available, and more attention to health system
strengthening, is needed to make headway in the fight to
roll back malaria
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